Results 11 to 20 of about 75,992 (272)
New-onset insulin-dependent diabetes due to nivolumab
Endocrinology, Diabetes & Metabolism Case Reports, 2018 Nivolumab, a monoclonal antibody against programmed cell death-1 receptor, is increasingly used in advanced cancers. While nivolumab use enhances cancer therapy, it is associated with increased immune-related adverse events.
Ali A Zaied +3 more
doaj +2 more sources
Acta OncologicaBackground and purpose: This study aims to evaluate neutrophil-to-eosinophil ratio (NER) as a prognostic and/or predictive biomarker in metastatic clear cell renal cell carcinoma (m-ccRCC) treated with nivolumab or ipilimumab/nivolumab.
Yana Beulque +15 more
doaj +4 more sources
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma [PDF]
, 2022 PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes.
Wagstaff, John; https://orcid.org/ +29 more
core +4 more sources
Therapeutics and Clinical Risk Management, 2019 Shi Zhou,* Samrat Khanal,* Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, People’s Republic of China *These authors contributed equally to this work Purpose: The aim of this study
Zhou S, Khanal S, Zhang H
doaj +1 more source
Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study
, 2021 To evaluate ICIs related dry eye and dry mouth in nivolumab therapy, 24 patients receiving nivolumab (group 1), 30 patients in remission without treatment for 6 months (group 2), 30 healthy participants (group 3) were cross-sectionally examined. Schirmer’
Kerem Poyraz (11466373) +7 more
core +1 more source
, 2023 lumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IVmelanoma,with benefit sustained at 4 years.
Gogas, Helen +7 more
core +1 more source
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC
Hepatology, EarlyView., 2022 Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu +11 more
wiley +1 more source
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab [PDF]
, 2021 [[abstract]]BACKGROUND: ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with ≥ 2 chemotherapy regimens.
Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Nishiyama, T;Chen, LT;Kang, YK
core +3 more sources
Genital lichen sclerosus after nivolumab [PDF]
, 2020 We report a patient with metastatic melanoma undergoing treatment with nivolumab who developed genital lichen sclerosus.
Soda, Giuseppe +2 more
core +1 more source